AzTrials
AzTrials

PresbyopiaACINCT00850031

Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes

A study testing AcuFocus Corneal Inlay in people with Presbyopia, run by AcuFocus, Inc. at 8 sites in 6 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will provide an effective method for the correction of presbyopia in patients who have normal distance vision but need a correction such as glasses or contact lenses to see clearly at near. Read more about this study

Who is it for?
Ages 45 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Presbyopia
What is being tested?
AcuFocus Corneal Inlay
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
119 participants
Where
8 sitesin 6 countries
Study dates
Jan 2009to Oct 2013
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Subjects must be natural emmetropes needing a minimum magnitude of +1.00D to +2.50D of reading add.
  • Subjects must have uncorrected near visual acuity worse than 20/40 and better than 20/100 in the eye to be implanted.
  • Subject must have distance visual acuity correctable to at least 20/20 in both eyes.
  • Subjects must have a preoperative spherical equivalent of plano defined as +0.50D to -0.75D with no more than 0.75D of refractive cylinder as determined by cycloplegic refraction in the eye to be implanted.

Who cannot join

  • Subjects with a difference of > 1.00D between the spherical equivalent manifest refraction and the spherical equivalent cycloplegic refraction.
  • Subjects with anterior segment pathology, including cataracts, in the eye to be implanted.
  • Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or any corneal abnormalities (including endothelial dystrophy, guttata, recurrent corneal erosion, etc.) in the eye to be implanted.
  • Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in the eye to be implanted.
  • Subjects with a history of chronic dry eye not responding to therapy.
  • Subjects with distorted or unclear corneal mires on topography maps of the eye to be implanted.
Show all 18Show fewer
  • Subjects who require canthotomy to generate a corneal flap in the eye to be implanted.
  • Subjects with macular degeneration, retinal detachment, or any other fundus pathology that would prevent an acceptable visual outcome in the eye to be implanted.
  • Subjects who have undergone previous intraocular or corneal surgery including cataract and LASIK surgery.
  • Subjects with a history of herpes zoster or herpes simplex keratitis.
  • Subjects who have a history of steroid-responsive rise in intraocular pressure, preoperative IOP > 21 mmHg, glaucoma, or is a glaucoma suspect.
  • Subjects with a history of diagnosed diabetes, autoimmune disease, connective tissue disease, or clinically significant atopic syndrome.
  • Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing, and any immunocompromised subjects.
  • Subjects who are using ophthalmic medication(s) other than artificial tears for treatment of any ocular pathology including ocular allergy.
  • Subjects using systemic medications with significant ocular side effects.
  • Subjects who are pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.
  • Subjects with known sensitivity to planned study concomitant medications.
  • Subjects who are participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.

Trial locations and contacts

8 sites in 6 countries.

8 sites in 6 countries

Australia2 sites
  • The Eye Institute

    Bondi Junction, 2022

  • Vista Laser Eye Clinics

    Melbourne, Victoria, 3185

Other trials in Australia

New Zealand2 sites
  • Auckland Eye

    Auckland

  • The Fendalton Eye Clinic

    Fendalton, Christchurch

Other trials in New Zealand

Austria1 site
  • Paracelsus Medizinische Privat-Universität, PMU, Universitätsklinikum

    Salzburg, 5020

Other trials in Austria

Germany1 site
  • Universitats-Augenklinik, Department of Ophthalmology

    Bochum, 44892

Other trials in Germany

Singapore1 site
  • Singapore National Eye Centre

    Singapore, 168751

Other trials in Singapore

United Kingdom1 site
  • Optical Express

    London, W1G 9AP

Other trials in United Kingdom

About this study

Official title: A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay (ACI)™ ACI 7000PDT in Presbyopic Subjects (OUS Study)

The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will provide an effective method for the correction of presbyopia in patients who have normal distance vision but need a correction such as glasses or contact lenses to see clearly at near.

Read the detailed description

The loss of near vision and the ability to perform tasks that require near vision is part of the normal aging process. This natural transformation in the eye occurs as a result of the loss of accommodation of the crystalline lens, a condition known as presbyopia. The crystalline lens is responsible for the accommodative properties of the human eye, as established by Young in 1801, over 200 years ago.1 During accommodation, the ciliary muscle contracts, decreasing tension on the zonules, and allowing the crystalline lens to thicken, increasing its refractive power. This mechanism of accommodation and thickening of the lens provides the eye with adequate refractive power for near vision. The loss of accommodation with aging is the result of changes in the crystalline lens composition that prevent the natural accommodative process from occurring. This is associated with the gradual loss of near vision without external correction, generally in the form of spectacles.

The AcuFocus™ ACI 7000PDT represents new technology based on the well-established concept of small-aperture optics. In early cameras, depth of focus was controlled by reducing the aperture through which light enters. The smaller the aperture, the greater the depth of focus will be. This concept also applies to the human eye. In the eye of a presbyopic emmetrope, the lens cannot accommodate sufficiently to focus the light rays from a near object onto a single point on the retina. Thus, a point object is imaged as a blur circle on the retina, and images of extended objects are degraded as well. If an opaque disc with a small aperture in the center is placed in front of the eye, the peripheral rays will be obscured while the central rays pass unaffected. Since peripheral rays enter the eye at a larger angle, they create a larger blur circle at the retinal image plane. Eliminating these peripheral rays reduces the size of the blur circle, improving image resolution.

In presbyopic subjects, objects closer than arm's length are focused behind the retina, thus creating blurred retinal images (which are composed of blur circles). A small aperture inlay placed in front of the eye of these subjects allows them to see at near by reducing the size of the blur circle.

AcuFocus, Inc. has developed a stationary intracorneal inlay designed to create a small aperture effect. The implant is intended to be placed intra-stromally either under a corneal flap or into a corneal pocket. Placement of the ACI will be centered over the pupil in the non-dominant eye. The ACI is expected to increase the depth of focus of the eye by reducing the circle of blur. Based on theoretical calculations of small aperture optics, the ACI is expected to provide presbyopic subjects with improvement of near and intermediate vision.

Conditions
Presbyopia
Being tested
AcuFocus Corneal Inlay
Keywords
Presbyopia, Accommodation, Near visual acuity, LASIK
Medical subject headings
Presbyopia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AcuFocus Corneal InlayDevice

    Also called AcuFocus Corneal Inlay ACI 7000 PDT, AcuFocus KAMRA inlay

    Inlay implanted in cornea for improvement of near vision

Study groups in NCT00850031
Study groupRoleWhat they receive
AcuFocus Corneal InlayExperimentalImplantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
Receives: Device: AcuFocus Corneal Inlay

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improvement in Uncorrected Near Visual Acuity

    Percent of subjects who achieved UCNVA of 20/40 or better.

    Measured: 12 months

Secondary outcomes (1)
  1. Improvement of Near Uncorrected Visual Acuity

    Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Feb 2009 (estimated)
  2. Study startJan 2009
  3. Primary completionOct 2013
  4. Study completionOct 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
119 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00850031
Sponsor's protocol ID
ACU-P08-020A
Acronym
ACI
Status last verified
Jan 2018
First submitted
20 Feb 2009
Last updated
28 Feb 2018
Data monitoring committee
No
Individual data sharing
No

Publications

  • Dexl AK, Seyeddain O, Riha W, Hohensinn M, Ruckl T, Hitzl W, Grabner G. Reading performance after implantation of a modified corneal inlay design for the surgical correction of presbyopia: 1-year follow-up. Am J Ophthalmol. 2012 May;153(5):994-1001.e2. doi: 10.1016/j.ajo.2011.08.044. Epub 2011 Nov 20.

    PubMed 22105801

Questions about this trial

What is this clinical trial studying?

A study testing AcuFocus Corneal Inlay in people with Presbyopia, run by AcuFocus, Inc. at 8 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in Australia, New Zealand, Austria, Germany, Singapore and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Feb 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improvement in Uncorrected Near Visual Acuity (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00850031, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in